A phase II, open-label, multi-arm study of novel combinations of immunotherapies or DDR inhibitors in platinum-refractory, extensive disease small-cell lung cancer (ED-SCLC): BALTIC.

Authors

Joachim Von Pawel

Asklepios Fachkliniken München-Gauting, Gauting, Germany

Joachim Von Pawel , Ihor Vynnychenko , Haiyi Jiang , Yifan Huang , Phillip A. Dennis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).

First Author: Matt D. Galsky

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.

First Author: Tanguy Y. Seiwert

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.

First Author: Thomas Powles

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).

First Author: Matt D. Galsky